natgillin/translations-raw huggingface dataset:
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema, particularly those with reduced cardiac reserve.
S trga so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
Študijo s pioglitazonom, kjer so spremljali kardiovaskularni izid, so opravili pri bolnikih, mlajših od 75 let z diabetesom mellitusom tipa 2 in že obstoječimi težjimi makrovaskularnimi boleznimi.
If ALT
Če kak bolnik
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/ or dark urine, liver enzymes should be checked.
15 razvije simptome, ki kažejo na moteno delovanje jeter, kar lahko vključuje nepojasnjeno slabost, bruhanje, bolečine v trebuhu, utrujenost, anoreksijo in/ ali temen urin, je treba kontrolirati jetrne encime.
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Očesne bolezni Pri tiazolidindionih, vključno s pioglitazonom, so v postmarketinških poročilih poročali o novonastalih ali poslabšanjih diabetičnega makularnega edema z zmanjšanjem vidne ostrine.
As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation.
16 Zaradi okrepitve delovanja insulina lahko zdravljenje s pioglitazonom pri bolnicah s sindromom policističnih jajčnikov povzroči obnovitev ovulacije.
15 Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6).
Zato se morajo tveganja za zanositev zavedati, in če bolnica želi zanositi ali zanosi, je treba zdravljenje prekiniti (glejte poglavje 4. 6).
Pioglitazone dose adjustment within the recommended Posology or changes in diabetic treatment should be considered (see section 4.5).
Pretehtati je potrebno prilagoditev odmerka pioglitazona v okviru priporočenega odmerjanja ali spremeniti zdravljenje diabetesa (glejte poglavje 4. 5).
Glustin tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
Tablete Glustin vsebujejo laktozo monohidrat z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/ galaktoze.
Close monitoring of glycaemic control should be considered (see section 4.4)
Pretehtati je potrebno skrbno spremljanje glikemičnega nadzora (glejte poglavje 4. 4).
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Pogostnosti so določene kot: zelo
Frequencies are defined as: very common > 1/ 10; common > 1/ 100 ,< 1/10; uncommon > 1/1000 ,< 1/100; rare > 1/ 10000 ,< 1/1000; very rare < 1/10000;
17 pogosti > 1/ 10; pogosti > 1/ 100, < 1/ 10; občasni > 1/ 1000, < 1/ 100; redki > 1/ 10000, < 1/ 1000; zelo redki < 1/ 10000; neznano (ocena ni možna iz danih podatkov).
16 not known (cannot be estimated from the available data).
MONOTERAPIJAS PIOGLITAZONOM
PIOGLITAZONE MONOTHERAPY
Očesne bolezni
Eye disorders Common: visual disturbance
Infekcijske in parazitske bolezni
PIOGLITAZONE IN COMBINATION THERAPY WITH METFORMIN
PIOGLITAZON V KOMBINIRANEM ZDRAVLJENJU Z METFORMINO
flatulence
Občasni:
Investigations
flatulenca
Common: weight increased
Pogosti:
Nervous system disorders Common: headache
Bolezni živčevja
Renal and urinary disorders Common: haematuria
Bolezni sečil
Reproductive system and breast disorders Common: erectile dysfunction
18 Motnje reprodukcije in dojk
PIOGLITAZONE IN COMBINATION THERAPY WITH SULPHONYLUREA
PIOGLITAZON V KOMBINIRANEM ZDRAVLJENJU S SULFONILSEČNINO
Ear and labyrinth disorders Uncommon:
Ušesne bolezni, vključno z motnjami labirinta
17 Gastrointestinal disorders Common: flatulence
Bolezni prebavil
General disorders and administration site conditions Uncommon:
Splošne težave in spremembe na mestu aplikacije
fatigue
Občasni:
Investigations
utrujenost
increased lactic dehydrogenase
Presnovne in prehranske motnje
Renal and urinary disorders Uncommon:
Bolezni sečil
glycosuria, proteinuria
glikozurija, proteinurija
sweating
znojenje
PIOGLITAZONE IN TRIPLE ORAL COMBINATION THERAPY WITH METFORMIN AND SULPHONYLUREA
POLIGLITAZON V TROJNEM PERORALNEM KOMBINIRANEM ZDRAVLJENJU Z METFORMINOM IN SULFONILSEČNINO
Investigations Common: weight increased, blood creatinine phosphokinase increased
povečana telesna masa, povišana kreatin fosfokinaza v krvi
Metabolism and nutrition disorders Common: hypoglycaemia
Presnovne in prehranjske motnje
Investigations Common: weight increase
Pogosti:
18 Cardiac disorders Common: heart failure
Pogosti:
Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic agents.
20 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri drugih hipoglikemičnih učinkovinah.
In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
V kliničnih preskušanjih pioglitazona je bila incidenca povišanih vrednosti ALT, višjih kot trikratna zgornja meja normalnih vrednosti, enaka kot pri placebu, vendar nižja kot v primerjalnih skupinah metformina ali sulfonilsečnine.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.
Povprečne koncentracije jetrnih encimov so se z zdravljenjem s pioglitazonom nižale.
However, this did not lead to an increase in mortality in this study.
V postmarketinških izkušnjah so se pojavljali redki primeri povišanih vrednosti jetrnih encimov in hepatocelularne disfunkcije.
Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.
Čeprav so v zelo redkih primerih poročali o smrtnem izidu, vzročno razmerje ni bilo ugotovljeno.
19 Hypoglycaemia may occur in combination with sulphonylureas or insulin.
V kombinaciji s sulfonilsečninami ali insulinom se lahko pojavi hipoglikemija.
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of therapy).
Za oceno časa do neuspeha zdravljenja (definirano kot pojav HbA1c ≥ 8, 0% po prvih šest mesecih zdravljenja) so klinično preskušanje pioglitazona v primerjavi z gliklazidom
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi, vendar ne klinično značilnimi povišanj ravni LDL holesterola.
20 In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
V PROaktivni študiji, ki ocenjuje kardiovaskularni izid, je bilo 5238 bolnikov z diabetesom mellitusom tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do 3, 5 let.
Almost all subjects (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Skoraj vsi preiskovanci (95%) so prejemale kardiovaskularna zdravila (beta blokatorje, ACE inhibitorje, antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, aspirin, statine, fibrate),
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone.
Vendar je bila
However, the incidence of oedema, weight gain and heart failure were increased.
22 incidenca edemov, pridobivanja telesne mase in srčnih odpovedi povečana.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Ta poteka predvsem prek citokromov P450 2C8 v manjši meri pa so lahko vpletene tudi druge izooblike.
21 Elderly Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.
Starejši Farmakokinetiki stanja dinamičnega ravnovesja sta pri bolnikih, starih 65 let in več, ter mladih osebah podobni.
22 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal
6. 6 Navodila za pripravo in ravnanje z zdravilom
Glustin 45 mg tablets.
Glustin 45 mg tablete
The tablets are white to off-white, round, flat and marked ‘ 45 ’ on one face, AD4 on the other.
Tablete so bele do umazano bele barve, okrogle, ploščate, z oznako ‘ 45 ’ na eni strani in AD4 na drugi.
24 Patients with renal impairment No dosage adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/ min) (see section 5.2).
26 Bolniki z okvarjenim delovanjem ledvic Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina > 4 ml/ min) odmerka ni treba prilagajati (glejte poglavje 5. 2).
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
Kardiovaskularno študijo izida s pioglitazonom so opravili pri bolnikih, mlajših od 75 let z diabetesom mellitusom tipa 2 in že obstoječimi težjimi makrovaskularnimi boleznimi.
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting,
Če kak bolnik
25 abdominal pain, fatigue, anorexia and/ or dark urine, liver enzymes should be checked.
27 razvije simptome, ki kažejo na moteno delovanje jeter, kar lahko vključuje nepojasnjeno slabost, bruhanje, bolečine v trebuhu, utrujenost, anoreksijo in/ ali temen urin, je treba kontrolirati jetrne encime.
As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation.
28 Zaradi okrepitve delovanja insulina lahko zdravljenje s pioglitazonom pri bolnicah s sindromom policističnih jajčnikov povzroči obnovitev ovulacije.
26 Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e. g. gemfibrozil) or inducers (e. g. rifampicin).
Pri uporabi pioglitazona in sočasnim dajanjem z zaviralci (npr. gemfibrozil) ali induktorji (npr. rifampicin) citokroma P450 2C8 je potrebna previdnost.
Frequencies are defined as: very common > 1/ 10; common > 1/ 100 ,< 1/10; uncommon > 1/1000 ,< 1/100; rare > 1/ 10000 ,< 1/1000; very rare < 1/10000; not known (cannot be estimated from the available data).
29 pogosti > 1/ 10; pogosti > 1/ 100, < 1/ 10; občasni > 1/ 1000, < 1/ 100; redki > 1/ 10000, < 1/ 1000; zelo redki < 1/ 10000; neznano (ocena ni možna iz danih podatkov).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
V V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
27 PIOGLITAZONE MONOTHERAPY
MONOTERAPIJA S PIOGLITAZONOM
Musculoskeletal system and connective tissue disorders Common:
Bolezni mišično- skeletnega sistema in vezivnega tkiva
Nervous system disorders Common:
Bolezni živčevja
Renal and urinary Common:
Bolezni sečil
disorders haematuria
Pogosti:
Reproductive system and breast disorders Common:
Pogosti:
Gastrointestinal disorders Common:
Bolezni prebavil
28 General disorders and administration site conditions Uncommon:
Splošne težave in spremembe na mestu aplikacije
Metabolism and nutritional disorders Uncommon:
Občasni:
appetite increased, hypoglycaemia
povečan apetit, hipoglikemija
Investigations Common:
Pogosti:
weight increased, blood creatinine phosphokinase increased
povečana telesna masa, povišana kreatin fosfokinaza v krvi
Musculoskeletal and connective tissue disorders Common:
Bolezni mišično- skeletnega sistema in vezivnega tkiva
Metabolism and nutrition disorders Common:
Pogosti:
Infections and infestations Common:
Pogosti:
29
POSTMARKETINŠKI PODATKI
POST-MARKETING DATA
Očesne bolezni
Eye disorders Not known macular oedema
Makularni edem:
Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic agents.
32 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri drugih hipoglikemičnih učinkovinah.
5.1 Pharmacodynamic properties
FARMAKOLOŠKE LASTNOSTI
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations.
Izboljšan nadzor glikemije je povezan z znižanjem plazemskih koncentracij insulina tako med
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom,, z majhnimi, vendar ne klinično značilnimi povišanj ravni LDL holesterola.
31 existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
V PROaktivni študiji, ki ocenjuje kardiovaskularni izid, je bilo 5238 bolnikov z diabetesom mellitusom tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do 3, 5 let.
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone.
Čeprav je bila študija neuspešna v povezavi z primarnimi opazovanimi dogodki, ki so zajemali smrtnost zaradi vseh razlogov, neusodne miokardne infarkte, kapi, akutne koronarne sindrome, težje amputacije nog, koronarne revaskularizacije in revaskularizacije nog, izsledki kažejo, da v zvezi z
On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal
Na tej podlagi je delež učinkovitosti M- IV enak približno trikratniku deleža pioglitazona, medtem ko je relativna učinkovitost M- II minimalna.
32 Patients with renal impairment In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar.
Bolniki z okvarjenim delovanjem ledvic Pri bolnikih z okvarjenim delovanjem ledvic so plazemske koncentracije pioglitazona in njegovih presnovkov nižje kot pri osebah z normalnim delovanjem ledvic, vendar je peroralni očistek izvorne učinkovine podoben.
Aluminium/ aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90 and 98 tablets
Aluminij/ aluminij pretisni omoti, pakiranja po 14, 28, 30, 50, 56, 84, 90 in 98 tablet.
33 Not all pack sizes may be marketed
Na trgu ni vseh navedenih pakiranj.
34 ANNEX II
37 DODATEK II
Bray Business Park Kilruddery County Wicklow Ireland
Irska
An updated Risk Management Plan should be provided as per the CHMP guideline on Risk Management System for medicinal products for human use.
Dopolnjen načrt o obvladovanju tveganja mora biti predložen v skladu s smernicami CHMP o sistemih obvladovanja tveganja za zdravila za uporabo v humani medicini.
36 ANNEX III
39 DODATEK III
38 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
41 PODATKI NA ZUNANJI OVOJNINI
Glustin 15 mg tablets Pioglitazone (as hydrochloride)
Glustin 15 mg tablete
EU/ 1/ 00/ 151/ 007 EU/ 1/ 00/ 151/ 001 EU/ 1/ 00/ 151/ 014 EU/ 1/ 00/ 151/ 002 EU/ 1/ 00/ 151/ 023 EU/ 1/ 00/ 151/ 015 EU/ 1/ 00/ 151/ 016 EU/ 1/ 00/ 151/ 003
EU/ 1/ 00/ 151/ 007 14 tablet EU/ 1/ 00/ 151/ 001 28 tablet EU/ 1/ 00/ 151/ 014 30 tablet EU/ 1/ 00/ 151/ 002 50 tablet EU/ 1/ 00/ 151/ 023 56 tablet EU/ 1/ 00/ 151/ 015 84 tablet EU/ 1/ 00/ 151/ 016 90 tablet EU/ 1/ 00/ 151/ 003 98 tablet
40 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
43 PODATKI NA ZUNANJI OVOJNINI
Glustin 30 mg tablets Pioglitazone (as hydrochloride)
Glustin 30 mg tablete
EU/ 1/ 00/ 151/ 008 EU/ 1/ 00/ 151/ 004 EU/ 1/ 00/ 151/ 017 EU/ 1/ 00/ 151/ 005 EU/ 1/ 00/ 151/ 024 EU/ 1/ 00/ 151/ 018 EU/ 1/ 00/ 151/ 019 EU/ 1/ 00/ 151/ 006
EU/ 1/ 00/ 151/ 008 14 tablet EU/ 1/ 00/ 151/ 004 28 tablet EU/ 1/ 00/ 151/ 017 30 tablet EU/ 1/ 00/ 151/ 005 50 tablet EU/ 1/ 00/ 151/ 024 56 tablet EU/ 1/ 00/ 151/ 018 84 tablet EU/ 1/ 00/ 151/ 019 90 tablet EU/ 1/ 00/ 151/ 006 96 tablet
42 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
45 PODATKI NA ZUNANJI OVOJNINI
Glustin 45 mg tablets Pioglitazone (as hydrochloride)
Glustin 45 mg tablete
EU/ 1/ 00/ 151/ 009 EU/ 1/ 00/ 151/ 010 EU/ 1/ 00/ 151/ 020 EU/ 1/ 00/ 151/ 011 EU/ 1/ 00/ 151/ 012 EU/ 1/ 00/ 151/ 021 EU/ 1/ 00/ 151/ 022 EU/ 1/ 00/ 151/ 013
EU/ 1/ 00/ 151/ 009 14 tablet EU/ 1/ 00/ 151/ 010 28 tablet EU/ 1/ 00/ 151/ 020 30 tablet EU/ 1/ 00/ 151/ 011 50 tablet EU/ 1/ 00/ 151/ 012 56 tablet EU/ 1/ 00/ 151/ 021 84 tablet EU/ 1/ 00/ 151/ 022 90 tablet EU/ 1/ 00/ 151/ 013 98 tablet
44 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
47 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Glustin 15 mg tablets Pioglitazone (as HCl)
Glustin 15 mg tablete
45 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
48 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Glustin 30 mg tablets Pioglitazone (as HCl)
Glustin 30 mg tablete
46 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
49 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Glustin 45 mg tablets Pioglitazone (as HCl)
Glustin 45 mg tablete
48 PACKAGE LEAFLET
51 NAVODILO ZA UPORABO GLUSTIN 15 mg TABLETE
GLUSTIN 15 MG TABLETS (Pioglitazone (as hydrochloride))
pioglitazon (v obliki pioglitazonijevega klorida)
Read all of this leaflet carefully before you start taking this medicine:
Pred začetkom jemanja natančno preberite navodilo!
What Glustin is and what it is used for 2.
Kaj je zdravilo Glustin in za kaj ga uporabljamo 2.
Before you take Glustin 3.
Kaj morate vedeti, preden boste vzeli zdravilo Glustin 3.
How to take Glustin 4.
Kako jemati zdravilo Glustin 4.
How to store Glustin 6.
Shranjevanje zdravila Glustin 6.
WHAT GLUSTIN IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO GLUSTIN IN ZA KAJ GA UPORABLJAMO
Glustin 15 mg tablets are an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus.
Glustin 15 mg tablete so antidiabetično zdravilo za zdravljenje diabetesa mellitusa tipa 2 (od insulina neodvisnega diabetesa).
This is the diabetes that usually develops in adulthood.
Ta vrsta diabetesa se običajno razvije v odrasli dobi.
Glustin 15 mg tablets helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.
Glustin 15 mg tablete pomagajo nadzorovati raven sladkorja v krvi, če imate diabetes mellitus tipa 2, in sicer tako, da telesu pomagajo bolje izkoristiti insulin, ki ga izdela.
Glustin 15 mg tablets may be used on their own or in combination with metformin and/ or a sulphonylurea which are also oral anti-diabetic medicines.
Glustin 15 mg tablete lahko uporabljamo same ali skupaj z metforminom in/ ali sulfonilsečnino, ki sta tudi peroralni antidiabetični zdravili.
Glustin 15 mg tablets may also be used in combination with insulin.
Glustin 15 mg tablete se lahko uporabljajo tudi v kombinaciji z insulinom.
BEFORE YOU TAKE GLUSTIN
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO GLUSTIN
Do not take Glustin 15 mg tablets:
Ne jemljite tablet Glustin 15 mg:
15 mg tablets.
- Če ste preobčutljivi za (alergični na) pioglitazon ali katerokoli sestavino tablet Glustin 15 mg.
Take special care with Glustin 15 mg tablets:
Bodite posebno pozorni pri jemanju tablet Glustin 15 mg:
- If you have a special type of diabetic eye disease called macular oedema (swelling of the back
- Če imate poseben tip diabetične očesne bolezni imenovane makularni edem (oteklina očesnega
of the eye).
ozadja).
There may be an increased possibility of your
Zaradi načina delovanja tega zdravila namreč lahko
becoming pregnant because of how your medicine works.
obstaja povečana verjetnost za zanositev.
49 Taking Glustin 15mg tablets with food and drink:
Jemanje tablet Glustin 15 mg skupaj s hrano in pijačo:
Important information about some of the ingredients of Glustin 15 mg tablets:
Pomembne informacije o nekaterih sestavinah zdravila Glustin 15 mg tablete:
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Glustin 15 mg tablets.
Če vam je vaš zdravnik povedal, da imate intoleranco za nekatere sladkorje, pokličite svojega zdravnika preden vzamete Glustin 15 mg tablete.
You can usually continue to take other medicines whilst you are being treated with Glustin 15 mg tablets.
Običajno lahko med zdravljenjem s tabletami Glustin 15 mg nadaljujete z jemanjem drugih zdravil.
HOW TO TAKE GLUSTIN
KAKO JEMATI ZDRAVILO GLUSTIN
If you have the impression that the effect of Glustin 15 mg tablets is too weak, talk to your doctor.
Če menite, da je učinek tablet Glustin 15 mg prešibak, se posvetujte z zdravnikom.
Glustin 15 mg tablets can be taken with or without food.
Tablete Glustin 15 mg lahko vzamete s hrano ali brez nje.
When Glustin 15 mg tablets are taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.
Če boste jemali tablete Glustin 15 mg skupaj z drugimi zdravili za zdravljenje diabetesa (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
Your doctor will ask you to have blood tests periodically during treatment with Glustin.
Zdravnik vas bo v času zdravljenja z Glustinom naročil na redne preiskave krvi.
If you are following a diabetic diet, you should continue with this while you are taking Glustin 15 mg tablets.
Če ste na diabetični dieti, jo med jemanjem tablet Glustin 15 mg nadaljujte.